Wells Fargo
CERE

Wells Fargo’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Wells Fargo’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,415
Closed -$57.9K – 7160
2024
Q2 		$57.9K Sell
1,415
-21,026
-94% -$876K ﹤0.01% 5240
2024
Q1 		$949K Buy
22,441
+2,298
+11% +$96.5K ﹤0.01% 3491
2023
Q4 		$854K Sell
20,143
-29,629
-60% -$851K ﹤0.01% 3539
2023
Q3 		$1.09M Sell
49,772
-13,857
-22% -$347K ﹤0.01% 3269
2023
Q2 		$2.02M Buy
63,629
+2,759
+5% +$84.7K ﹤0.01% 2910
2023
Q1 		$1.48M Buy
60,870
+44,954
+282% +$1.32M ﹤0.01% 3110
2022
Q4 		$502K Buy
15,916
+13,905
+691% +$392K ﹤0.01% 3638
2022
Q3 		$57K Sell
2,011
-283
-12% -$8.43K ﹤0.01% 4899
2022
Q2 		$61K Sell
2,294
-7,394
-76% -$210K ﹤0.01% 4935
2022
Q1 		$339K Sell
9,688
-13,793
-59% -$403K ﹤0.01% 4679
2021
Q4 		$761K Sell
23,481
-23,388
-50% -$825K ﹤0.01% 4337
2021
Q3 		$1.38M Buy
+46,869
New +$1.32M ﹤0.01% 3968
2021
Q2 		– Sell
-1
Closed – – 7617
2021
Q1 		$0 Sell
1
-239
-100% -$3.5K ﹤0.01% 7541
2020
Q4 		$4K Buy
+240
New +$3.12K ﹤0.01% 6204

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Wells Fargo's CERE Position: Q3 2024 in Review

Wells Fargo sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,415 shares — an estimated $57.9K sold.

Wells Fargo first reported a position in CERE in Q4 2020 and held it in 14 quarters. The position peaked at $2.02M in Q2 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Wells Fargo reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Wells Fargo sold 1,415 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $57.9K.
  • Wells Fargo first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Wells Fargo's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.02M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.